Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Up 2,181.4% in December

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 160,265 shares, an increase of 2,181.4% from the December 15th total of 7,025 shares. Currently, 5.1% of the company’s shares are short sold. Based on an average daily trading volume, of 5,492,427 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 5,492,427 shares, the days-to-cover ratio is presently 0.0 days. Currently, 5.1% of the company’s shares are short sold.

Institutional Trading of Athira Pharma

An institutional investor recently bought a new position in Athira Pharma stock. Focus Partners Wealth acquired a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned about 0.21% of Athira Pharma as of its most recent SEC filing. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Stock Down 4.2%

Shares of NASDAQ ATHA traded down $0.30 during midday trading on Monday, hitting $6.89. The stock had a trading volume of 69,689 shares, compared to its average volume of 3,210,973. The company has a market capitalization of $27.17 million, a price-to-earnings ratio of -0.71 and a beta of 2.79. Athira Pharma has a 1-year low of $2.20 and a 1-year high of $8.36. The company has a fifty day moving average price of $5.26 and a 200 day moving average price of $4.38.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). On average, research analysts forecast that Athira Pharma will post -2.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ATHA. Mizuho set a $4.00 target price on shares of Athira Pharma in a research report on Friday, September 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell” and a consensus target price of $4.00.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.